1. P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. (27th May 2021) Authors: Attauabi, M; Höglund, C; Fassov, J; Pedersen, K B; Bansholm Hansen, H; Wildt, S; Dam Jensen, M; Neumann, A; Lind, C; Albæk Jacobsen, H; Popa, A M; Kjeldsen, J; Pedersen, N; Molazahi, A; Haderselv, K; Aalykke, C; Knudsen, T; Cebula, W; Munkholm, P; Bendtsen, F Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey. (15th January 2020) Authors: Volmar, S; Wildt, S; Munck, L K Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗